Accessing Hepatitis <scp>C</scp> patients who are difficult to reach: it is time to overcome barriers
-
- P. Bruggmann
- Arud Centres of Addiction Medicine Zurich Switzerland
説明
<jats:title>Summary</jats:title><jats:p>With the arrival of simple, efficient and safe interferon‐free treatment regimens, hepatitis <jats:styled-content style="fixed-case">C</jats:styled-content> virus (<jats:styled-content style="fixed-case">HCV</jats:styled-content>) therapy will have the potential to be successfully used for the majority of infected patients and prevent the associated morbidity and mortality. With the current treatment uptake rates, only a very small proportion of <jats:styled-content style="fixed-case">HCV</jats:styled-content>‐infected patients are reached. Paradoxically, treatment rates are lowest in the most affected at‐risk group – people who inject drugs (<jats:styled-content style="fixed-case">PWID</jats:styled-content>) – which is the major driving force behind the spread of <jats:styled-content style="fixed-case">HCV</jats:styled-content> infection. To conquer the increasing problem of <jats:styled-content style="fixed-case">HCV</jats:styled-content>‐related liver disease, many existing but modifiable obstacles, which prevent detection, assessment and treatment uptake, have to be overcome in this population. This review article summarizes the existing literature on the most relevant barriers preventing <jats:styled-content style="fixed-case">HCV</jats:styled-content> care and describes measures to overcome these obstacles.</jats:p>
収録刊行物
-
- Journal of Viral Hepatitis
-
Journal of Viral Hepatitis 19 (12), 829-835, 2012-10
Wiley